New Insights into Immunotherapy for Gynecological Cancer
Author:
Open Access
- 20 July 2022
- journal article
- editorial
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (14) , 4198
Abstract
Gynecologic malignancies are a heterogeneous group of female reproductive system tumors, including cervical, endometrial, ovarian, vaginal, and vulval cancers, and are the second most commonly diagnosed female cancers around the worldKeywords
This publication has 30 references indexed in Scilit:
- Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Pathophysiological Roles of Ezrin/Radixin/Moesin ProteinsBiological and Pharmaceutical Bulletin, 2017
- Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature reviewCritical Reviews in Oncology/Hematology, 2016
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic FactorsImmunity, 2016
- Regulation of ErbB2 localization and function in breast cancer cells by ERM proteinsOncotarget, 2016
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial CancerInternational Journal of Gynecological Cancer, 2016
- Changing paradigms in the systemic treatment of advanced cervical cancerAmerican Journal of Obstetrics and Gynecology, 2016
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian CancerJournal of Clinical Oncology, 2015
- Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013